Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Holger Schmid. (2016) Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure. Expert Review of Hematology 9:1, pages 5-20.
Read now
Read now
Ma Teresa González, Rosa Ramos, Manel Vera, Francesc Barbosa, Carmen Garcia, Isabel Garcia, Carlota González-Segura, Marc Cuxart, Josep Teixidó & Juan José de la Cruz. (2013) Monthly CERA Treatment Maintains Stable Hemoglobin Levels in Routine Clinical Practice of Peritoneal Dialysis Patients. Renal Failure 35:3, pages 314-319.
Read now
Read now
Naro Ohashi, Yukitoshi Sakao, Hideo Yasuda, Akihiko Kato & Yoshihide Fujigaki. (2012) Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease. International Journal of Nephrology and Renovascular Disease 5, pages 53-60.
Read now
Read now
Francesco Locatelli & Lucia Del Vecchio. (2012) An expert opinion on the current treatment of anemia in patients with kidney disease. Expert Opinion on Pharmacotherapy 13:4, pages 495-503.
Read now
Read now
Brigitte Schiller & Anatole Besarab. (2011) Simplifying anemia management in hemodialysis patients: ESAs administered at longer dosing intervals can enhance opportunities to provide patient-focused care. Current Medical Research and Opinion 27:8, pages 1539-1550.
Read now
Read now
D. Fliser, W. Kleophas, F. Dellanna, R.E. Winkler, W. Backs, U. Kraatz, W. Fassbinder, V. Wizemann & G. Strack. (2010) Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Current Medical Research and Opinion 26:5, pages 1083-1089.
Read now
Read now
Joel Michels Topf. (2008) CERA: third-generation erythropoiesis-stimulating agent. Expert Opinion on Pharmacotherapy 9:5, pages 839-849.
Read now
Read now
Francesco Locatelli & Bruno Reigner. (2007) C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. Expert Opinion on Investigational Drugs 16:10, pages 1649-1661.
Read now
Read now
Articles from other publishers (38)
Yoondam Seo, Jisoo Park, Hyeon-Jeong Lee, Minyoung Kim, Inseon Kang, Junghyun Son, Min-Kyu Oh & Hophil Min. (2023) Development and validation of a method for analyzing the sialylated glycopeptides of recombinant erythropoietin in urine using LC–HRMS. Scientific Reports 13:1.
Crossref
Crossref
Edmund YM Chung, Suetonia C Palmer, Valeria M Saglimbene, Jonathan C Craig, Marcello Tonelli & Giovanni FM Strippoli. (2023) Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database of Systematic Reviews 2023:2.
Crossref
Crossref
Yves Dimitrov, Julie Rieger, Thierry Krummel, Philippe Petitjean, Alexandre Klein, François Chantrel, Nicolas Meyer & Thierry Hannedouche. (2020) CERA conversion to darbepoetin alfa in 154 hemodialysis patients. International Urology and Nephrology 52:10, pages 1979-1985.
Crossref
Crossref
María Rocío Villegas, Alejandro Baeza & María Vallet-Regí. (2018) Nanotechnological Strategies for Protein Delivery. Molecules 23:5, pages 1008.
Crossref
Crossref
Valeria M Saglimbene, Suetonia C Palmer, Marinella Ruospo, Patrizia Natale, Jonathan C Craig & Giovanni FM Strippoli. (2017) Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews 2017:8.
Crossref
Crossref
Francesco Locatelli, Gabriel Choukroun, Matt Truman, Alfons Wiggenhauser & Danilo Fliser. (2016) Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials. Advances in Therapy 33:4, pages 610-625.
Crossref
Crossref
Suetonia C Palmer, Valeria Saglimbene, Dimitris Mavridis, Georgia Salanti, Jonathan C Craig, Marcello Tonelli, Natasha Wiebe & Giovanni FM Strippoli. (2014) Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Noor Alsalimy & Ahmed Awaisu. (2014) Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review. International Journal of Clinical Pharmacy 36:6, pages 1115-1125.
Crossref
Crossref
Aleix Cases, José Portolés, Jordi Calls, Alberto Martinez-Castelao, María Antonia Munar & Alfonso Segarra. (2014) Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study. International Urology and Nephrology 46:10, pages 1983-1995.
Crossref
Crossref
Bradley A. Warady & Douglas M. Silverstein. (2013) Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease. Pediatric Nephrology 29:9, pages 1493-1505.
Crossref
Crossref
. Experimental and Clinical Transplantation 12:3.
Crossref
Crossref
Deirdre Hahn, June D Cody & Elisabeth M Hodson. (2014) Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. Cochrane Database of Systematic Reviews 2014:11.
Crossref
Crossref
Klemens Budde, Thomas Rath & Volker Kliem. (2014) Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study. Journal of Transplantation 2014, pages 1-10.
Crossref
Crossref
Fuat Bozkurt & Heribert-Ewald Fink. (2013) Hemoglobin Stability and Patient Satisfaction After Switch to C.E.R.A. Therapy: A Multicenter, Observational Study. Clinical Drug Investigation 33:12, pages 939-940.
Crossref
Crossref
Michael Koch, Wolfgang Treiber & Danilo Fliser. (2013) Effective Achievement of Hemoglobin Stability with Once-Monthly C.E.R.A. in Peritoneal Dialysis Patients: A Prospective Study. Clinical Drug Investigation 33:10, pages 699-706.
Crossref
Crossref
Kleyton Bastos, Luis Antonio Lucarelli, Elizabeth De Francesco-Daher, Roberto Pecoits Filho, Carlos Henríquez, Beatriz Espinoza, Ignacio Villanueva, Emma Schwedt, Ruben Schiavelli & Ricardo Correa-Rotter. (2012) C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis. International Urology and Nephrology 45:5, pages 1355-1364.
Crossref
Crossref
María Dolores Albero Molina, Ramón López-Menchero Martínez, Carlos del Pozo Fernández, Luis Álvarez Fernández & Laura Sánchez Rodríguez. (2013) Eficiencia de la administración mensual subcutánea de metoxi-polietilenglicol epoetina β (Mircera®) en pacientes estables en hemodiálisis previamente tratados con eritropoyetinaEficiencia de la administración sc mensual de MIRCERA en pacientes en HD. Diálisis y Trasplante 34:3, pages 93-100.
Crossref
Crossref
Ana I. Sánchez-Fructuoso, Juan C. Ruiz, José V. Torregrosa, Esther González, Ernesto Gómez, Roberto J. Gallego, María I. Troya, Carlos Jimenez, Francisco Llamas, Rafael Romero, Carmen Bernis, José F. Crespo & Luis Guirado. (2012) Anemia Control in Renal Transplant Recipients Receiving Continuous Erythropoietin Receptor Activator (C.E.R.A.) Treatment: The AnemiaTrans Study. Advances in Therapy 29:11, pages 979-991.
Crossref
Crossref
Nataša Debeljak & Arthur J. Sytkowski. (2012) Erythropoietin and erythropoiesis stimulating agents. Drug Testing and Analysis 4:11, pages 805-812.
Crossref
Crossref
Stefan Heidenreich, Frank Leistikow, Stefan Zinn, Jörg Baumann, Andreas Atzeni, Vitomir Bajeski, Jörn Dietzmann & Gert-Peter Dragoun. (2012) Monthly Administration of a Continuous Erythropoietin Receptor Activator Provides Efficient Haemoglobin Control in Non-Dialysis Patients during Routine Clinical Practice. Clinical Drug Investigation 32:2, pages 99-110.
Crossref
Crossref
John K. Leypoldt, Mahmoud Loghman‐Adham, Paul Jordan & Bruno Reigner. (2011)
Effect of hemodialysis and hemofiltration on plasma
C.E.R.A
. concentrations
. Hemodialysis International 16:1, pages 20-30.
Crossref
Crossref
Francesco Locatelli & Lucia Del Vecchio. (2011) Erythropoiesis-Stimulating Agents in Renal Medicine. The Oncologist 16:S3, pages 19-24.
Crossref
Crossref
F. Dellanna, R. E. Winkler, F. Bozkurt, V. Schettler, S. Graf, N. Bockreiss & D. Fliser. (2011) Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study. International Journal of Clinical Practice 65:1, pages 64-72.
Crossref
Crossref
Steevens N. S. Alconcel, Arnold S. Baas & Heather D. Maynard. (2011) FDA-approved poly(ethylene glycol)–protein conjugate drugs. Polymer Chemistry 2:7, pages 1442.
Crossref
Crossref
A. Sánchez-Fructuoso, L. Guirado, J.C. Ruiz, V. Torregrosa, E. González, M.L. Suárez & R. Gallego. (2010) Anemia Control in Kidney Transplant Patients Treated With Methoxy Polyethylene Glycol-Epoetin Beta (Mircera): The Anemiatrans Group. Transplantation Proceedings 42:8, pages 2931-2934.
Crossref
Crossref
Wolfgang Jelkmann. (2010) Biosimilar epoetins and other “follow‐on” biologics: Update on the European experiences. American Journal of Hematology 85:10, pages 771-780.
Crossref
Crossref
Pascal Chanu, Ronald Gieschke, Jean‐Eric Charoin, Anne Pannier & Bruno Reigner. (2013) Population Pharmacokinetic/Pharmacodynamic Model for C.E.R.A. in Both ESA‐Naïve and ESA‐Treated Chronic Kidney Disease Patients With Renal Anemia. The Journal of Clinical Pharmacology 50:5, pages 507-520.
Crossref
Crossref
Anantha Vijay R. Santhanam, Livius V. d'Uscio & Zvonimir S. Katusic. 2010. Cardiovascular Pharmacology - Endothelial Control. Cardiovascular Pharmacology - Endothelial Control
257
285
.
B. Knebelmann. (2009) Stabilité de l’hémoglobine : résultats d’essais cliniques. Néphrologie & Thérapeutique 5:5, pages 15-20.
Crossref
Crossref
Francesco Locatelli & Lucia Del Vecchio. (2008) Optimizing the management of renal anemia: challenges and new opportunities. Kidney International 74, pages S33-S37.
Crossref
Crossref
F. Locatelli, A. Covic, K.-U. Eckardt, A. Wiecek & R. Vanholder. (2008) Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation 24:2, pages 348-354.
Crossref
Crossref
B. Canaud, G. Mingardi, J. Braun, P. Aljama, P. G. Kerr, F. Locatelli, G. Villa, B. Van Vlem, A. W. McMahon, C. Kerloeguen & U. Beyer. (2008) Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation 23:11, pages 3654-3661.
Crossref
Crossref
Monique P Curran & Paul L McCormack. (2008) Methoxy Polyethylene Glycol-Epoetin Beta. Drugs 68:8, pages 1139-1156.
Crossref
Crossref
Bruce Spinowitz, Daniel W. Coyne, Charmaine E. Lok, Mario Fraticelli, Maher Azer, Sanjay Dalal, Giuseppe Villa, Steven Rosansky, Helena Adamis & Ulrich Beyer. (2008) C.E.R.A. Maintains Stable Control of Hemoglobin in Patients with Chronic Kidney Disease on Dialysis when Administered Once Every Two Weeks. American Journal of Nephrology 28:2, pages 280-289.
Crossref
Crossref
Marian Klinger, Manual Arias, Vassilis Vargemezis, Anatole Besarab, Wladyslaw Sulowicz, Trevor Gerntholtz, Kazimierz Ciechanowski, Frank C. Dougherty & Ulrich Beyer. (2007) Efficacy of Intravenous Methoxy Polyethylene Glycol-Epoetin Beta Administered Every 2 Weeks Compared With Epoetin Administered 3 Times Weekly in Patients Treated by Hemodialysis or Peritoneal Dialysis: A Randomized Trial. American Journal of Kidney Diseases 50:6, pages 989-1000.
Crossref
Crossref
Nathan W Levin, Steven Fishbane, Francisco Valdés Cañedo, Steven Zeig, George M Nassar, John E Moran, Giuseppe Villa, Ulrich Beyer & Delphine Oguey. (2007) Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). The Lancet 370:9596, pages 1415-1421.
Crossref
Crossref
Wladyslaw Sulowicz, Francesco Locatelli, Jean-Philippe Ryckelynck, Jozsef Balla, Botond Csiky, Kevin Harris, Patricia Ehrhard & Ulrich Beyer. (2007) Once-Monthly Subcutaneous C.E.R.A. Maintains Stable Hemoglobin Control in Patients with Chronic Kidney Disease on Dialysis and Converted Directly from Epoetin One to Three Times Weekly. Clinical Journal of the American Society of Nephrology 2:4, pages 637-646.
Crossref
Crossref
Anatole Besarab, Moro O. Salifu, N. Martin Lunde, Vinod Bansal, Steven Fishbane, Frank C. Dougherty & Ulrich Beyer. (2007) Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: A 19-week, phase ii, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Clinical Therapeutics 29:4, pages 626-639.
Crossref
Crossref